Methods of treating cancer in a subject and compositions are provided. The methods include administering a therapeutically effective amount of a poly (ADP ribose) polymerase (PARP) inhibitor to the subject in need thereof and administering a therapeutically effective amount of a folic acid supplement to the subject. Also described herein are methods for identifying a subject having cancer and having an elevated folate receptor expression level relative to a folate receptor expression level in a subject free of cancer and administering a therapeutically effective amount of a PARP inhibitor to the subject having the elevated folate receptor level. Also described herein are compositions including a PARP inhibitor and a folic acid supplement.

Methods of treating cancer in a subject and compositions are provided. The methods include administering a therapeutically effective amount of a poly (ADP ribose) polymerase (PARP) inhibitor to the subject in need thereof and administering a therapeutically effective amount of a folic acid supplement to the subject. Also described herein are methods for identifying a subject having cancer and having an elevated folate receptor expression level relative to a folate receptor expression level in a subject free of cancer and administering a therapeutically effective amount of a PARP inhibitor to the subject having the elevated folate receptor level. Also described herein are compositions including a PARP inhibitor and a folic acid supplement.

Disclosed is a novel means that is effective for analgesia or sedation. The analgesic or sedative agent of the present invention comprises, an active component, disulfiram, a metal complex of diethyldithiocarbamate, a disulfide capable of generating diethyldithiocarbamate in the body, a pharmaceutically acceptable salt of any of these compounds, or a solvate of any of these compounds or salts thereof. Disulfiram and the above-described metal complex are known to have anticancer and anti-inflammatory effects. The agent of the present invention can exert multiple therapeutic benefits such as anticancer, anti-inflammatory, analgesic, and sedative effects, in cancer patients.

The compositions of this disclosure provide broad-spectrum nutrient supplementation to support the health of multiple organ and tissue systems in which mitochondrial function plays a fundamental role. In particular, the formulations promote neuroprotective, cardioprotective, immunosupportive, and anti-aging benefits. Also provided herein are novel, neuroprotective preparations containing a combination of broad- or full-spectrum hemp oil extract combined with niacinamide, a non-flushing form of vitamin B3, and methods of use are described allowing for safe, effective, and convenient use of a neuroprotective, antioxidant preparation for general and clinical use.

The compositions of this disclosure provide broad-spectrum nutrient supplementation to support the health of multiple organ and tissue systems in which mitochondrial function plays a fundamental role. In particular, the formulations promote neuroprotective, cardioprotective, immunosupportive, and anti-aging benefits. Also provided herein are novel, neuroprotective preparations containing a combination of broad- or full-spectrum hemp oil extract combined with niacinamide, a non-flushing form of vitamin B3, and methods of use are described allowing for safe, effective, and convenient use of a neuroprotective, antioxidant preparation for general and clinical use.

Disclosed herein is a method of treating patients with NSCLC subtypes of cancer by reducing tumor burden, comprising administering at least one dose of purified Ruthenium (III) Pyrazole complexes to patients suffering from NSCLC, wherein said dose is therapeutically sufficient. In one or more embodiments, the Ruthenium III Pyrazole is RuCl.sub.3(DMSO)(dmPyz).sub.2.

Disclosed herein is a method of treating patients with NSCLC subtypes of cancer by reducing tumor burden, comprising administering at least one dose of purified Ruthenium (III) Pyrazole complexes to patients suffering from NSCLC, wherein said dose is therapeutically sufficient. In one or more embodiments, the Ruthenium III Pyrazole is RuCl.sub.3(DMSO)(dmPyz).sub.2.

Methods for treating Wilson Disease with bis-choline tetrathiomolybdate therapy are provided. The methods may include administering 15 mg or between 30 and 90 mg of bis-choline tetrathiomolybdate once daily to a patient exhibiting NCC.sub.corrected, alanine aminotransferase (ALT), hemoglobin, platelets, or neutrophils levels meeting specified criteria. The methods may include modifying treatment by decreasing or increasing the daily dose of bis-choline tetrathiomolybdate or discontinuing treatment for a period of time.

The present invention relates to a method for the evaluation of tissue gadolinium deposition that offers advantages compared with known methods. Comparison of different gadolinium-based contrast agents (GBCAs) based on retention, organ distribution, washout and safety is facilitated using the methods of the present invention.

An oral rinse including ionic silver as silver citrate complex and acemannan is useful for the treatment of oral ulceration and oral mucositis. The oral rinse has shown effectiveness against fungal and bacteria species such as Candida species, Staphylococcus aureus and Streptococcus pyogenes.